Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Anna Korycka-Wołowiec"'
Autor:
Dagmara Szmajda-Krygier, Adrian Krygier, Krzysztof Jamroziak, Anna Korycka-Wołowiec, Marta Żebrowska-Nawrocka, Ewa Balcerczak
Publikováno v:
Current Issues in Molecular Biology, Vol 44, Iss 8, Pp 3455-3464 (2022)
The genetic factors of adult acute lymphoblastic leukemia (ALL) development are only partially understood. The Runt-Related Transcription Factor (RUNX) gene family play a crucial role in hematological malignancies, serving both a tumor suppressor and
Externí odkaz:
https://doaj.org/article/f246a84d101446e381967d6c95ef8566
Publikováno v:
Acta Haematologica Polonica. 53:104-111
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e08ec130fc83b2d093a1de3208c6b5e2
https://doi.org/10.5603/ahp.a2022.0014
https://doi.org/10.5603/ahp.a2022.0014
Autor:
Aleksandra Kubiak, Dariusz Wołowiec, Tadeusz Robak, Anna Korycka-Wołowiec, Ewelina Ziolkowska
Publikováno v:
Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 31(9)
Venetoclax (VEN), a highly selective BCL-2 inhibitor, is successfully used in the treatment of chronic lymphocytic leukemia (CLL). The purine analogue - cladribine (2-CdA) - is also administered to CLL patients, especially as a part of chemoimmunothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebf5a0cfcf12e4590eb815652d92af67
https://pubmed.ncbi.nlm.nih.gov/35467089
https://pubmed.ncbi.nlm.nih.gov/35467089
Publikováno v:
In Acta Haematologica Polonica 2012 43(3):277-284
Publikováno v:
Acta Haematologica Polonica. 50:41-50
StreszczenieWenetoklaks jest przedstawicielem nowej grupy leków, których mechanizm działania polega na zahamowaniu ekspresji antyapoptotycznych białek rodziny BCL-2. Białka te należą do głównych regulatorów wewnątrzpochodnego szlaku apopto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10a7c7a2d3b384e201e89115af20aac9
https://doi.org/10.2478/ahp-2019-0008
https://doi.org/10.2478/ahp-2019-0008
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 15:353-366
Venetoclax, an antagonist of BCL-2 protein plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). It has been approved by the FDA for the treatment of relapsed/refractory CLL with del17p, and by the EMA for patients with d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d6af8d1ffc2a713f04231b1aed8d977
https://doi.org/10.1080/17425255.2019.1606211
https://doi.org/10.1080/17425255.2019.1606211
Publikováno v:
Expert opinion on drug safety. 19(11)
Conventional treatment for mantle cell lymphoma (MCL) patients includes regimens combining rituximab with other cytotoxic drugs, followed or not by consolidation with autologous stem cell transplantation and rituximab maintenance. However, older, unf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f81371d28303b83e6101e5e9dba45cd7
https://pubmed.ncbi.nlm.nih.gov/32946324
https://pubmed.ncbi.nlm.nih.gov/32946324
Autor:
Ewa Balcerczak, Dariusz Wołowiec, Maciej Borowiec, Tadeusz Robak, Pawel Karpinski, Ewa Lech-Marańda, Ewelina Ziolkowska, Maria M. Sasiadek, Jerzy Z. Blonski, Anna Korycka-Wołowiec
Publikováno v:
Leukemialymphoma. 60(6)
We studied whether bendamustine (BENDA) alone or with rituximab (RIT) modifies in vitro expression of apoptosis-involved genes and proteins of chronic lymphocytic leukemia (CLL) cells depending on ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dee76ec485823603b90a0ed66b14e35
https://pubmed.ncbi.nlm.nih.gov/30187811
https://pubmed.ncbi.nlm.nih.gov/30187811
Autor:
Piotr Smolewski, Dariusz Wołowiec, Anna Korycka-Wołowiec, Jerzy Z. Blonski, Ewelina Ziolkowska, Tadeusz Robak, Barbara Cebula-Obrzut
Publikováno v:
Postępy Higieny i Medycyny Doświadczalnej, Vol 68, Pp 1433-1443 (2014)
Aim The aim of our study was to compare the cytotoxic effects of bendamustine (BENDA) and rituximab (RIT) used either alone or in combination and to evaluate the influence of the above mentioned drugs on apoptosis measured as changes in mitochondrial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b880e2aad17f24af968d7d266f8f367
https://doi.org/10.5604/17322693.1130704
https://doi.org/10.5604/17322693.1130704
Publikováno v:
ISRN Oncology
Chronic lymphocytic leukemia (CLL) is characterized by the clonal proliferation and accumulation of mature B lymphocytes. CLL cells show an antiapoptotic profile, suggesting the important role of apoptosis inhibition in the disease development. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b9ad96f585938be7a42f72548a124a0
https://doi.org/10.1155/2013/740615
https://doi.org/10.1155/2013/740615